Lupin and Sun settle Bromsite patent suit after ruling
Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.
MSF urges South Africa to open access to COVID-19 generics
Humanitarian organisation Médecins Sans Frontières has called for the South African government to seek the revocation of COVID-19-related patents granted to Eli Lilly and Moderna.
AstraZeneca, MSD sue MSN and Sandoz over Calquence generics
AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.
EC reveals plans for unitary SPC, compulsory licences
The European Commission will unveil plans to make supplementary protection certificates more accessible and efficient for pharmaceutical companies to register and enforce by the end of March.
PhRMA says EU, WTO, others are ‘weakening’ IP
Pharmaceutical industry consortium PhRMA has asked the Office of the US Trade Representative to put the European Union, the World Trade Organization and the UK on a watch list of trading partners that could “weaken” IP rights.
Pfizer accuses ex-employees of stealing trade secrets for startup
Pfizer has sued two of its former executive staffers, alleging that they stole trade secrets related to diabetes medication before leaving the company.
Gilead pays $1.25bn to GSK in HIV drug settlement
Gilead Sciences has agreed to pay $1.25 billion upfront with additional royalties to GlaxoSmithKline subsidiary ViiV Healthcare to settle claims that it infringed HIV drug patents.
Court dismisses Regeneron’s antitrust countersuit against Novartis
Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
Labour peer says vaccine IP should be waived during a pandemic
UK politicians are proposing that the country waive UK registered IP related to vaccines and treatments in the event of a pandemic.
Celgene, Dr Reddy's abandon cancer drug patent dispute
Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.
